MedPath

Comparison of two blood tests in predicting risk of death in patients with blood infection

Not yet recruiting
Conditions
Sepsis, unspecified organism,
Registration Number
CTRI/2018/08/015371
Lead Sponsor
ALL INDIA INSTITUTE OF MEDICAL SCIENCES
Brief Summary

IN ALL PATIENTS MEETING THE INCLUSION CRITERIA A BLOOD SAMPLE WILL BE DRAWN AND INITIAL SERUM LACTATE AS WELL AS NEUTOPHIL LYMPHOCYTE COUNT RATIO AT THE TIME OF PRESENTATION WILL BE CALCULATED.  AT 6 HOURS INTERVAL OF PRESENTATION SERUM LACTATE VALUE WILL BE MEASURED . LACTATE CLEARANCE WILL BE CALCULATED . THE ABILITY OF LACTATE CLEARANCE AND NEUTROPHIL LYMPHOCYTE COUNT RATIO IN PREDICTING 28 DAYS MORTALITY WILL BE COMPARED AND CORRELATION BETWEEN THEM ASSESSED.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

1.PATIENTS WITH PRESUMED BACTERIAL SEPSIS (DEFINED AS POSITIVE qSOFA OR INCREASE IN SOFA SCORE BY TWO OR MORE POINTS) AND INITIAL LACTATE VALUE GREATER THAN 2 mmol PER LITRE.

Exclusion Criteria
  • PATIENTS WITH ESRD 2.
  • PATIENTS ON HEMODIALYSIS AKI ACUTE CEREBROVASCULAR ACCIDENT ACUTE CORONARY SYNDROME ACUTE PULMONARY OEDEMA STATUS ASTHMATICUS SEIZURE TRAUMA UNCONTROLLED HAEMORRHAGE THOSE RECEIVING CORTICOSTEROID.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
28 DAYS MORTALITY DIFFERENCE BETWEEN LACTATE CLEARANCE GREATER THAN 20 PERCENT OF BASELINE VERSUS LESS THAN 20 PERCENT OF BASELINE AND BETWEEN NLR MORE THAN 7 VERSUS LESS THAN 728 DAYS
Secondary Outcome Measures
NameTimeMethod
CORRELATION BETWEEN LACTATE CLEARANCE AND NLR28 DAYS

Trial Locations

Locations (1)

ALL INDIA INSTITUTE OF MEDICAL SCIENCES

🇮🇳

South, DELHI, India

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
🇮🇳South, DELHI, India
SHIV AKSHAT
Principal investigator
9654465389
drshivakshat@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.